Halozyme Therapeutics, Inc. (HALO) 2023年年度报告「NASDAQ」.pdf

1、2023 Annual ReportWe are proud of the many milestones and accomplishments that we achieved as an organization and with our partners throughout the year.These accomplishments supported another year of record growth while also serving as a strong foundation for our future growth.In 2023,we increased t

2、he total number of ENHANZE commercial partner products from 5 to 7,with the approval of argenxs VYVGART Hytrulo for generalized myasthenia gravis in the U.S.and EU and the approval of Roches Tecentriq SC in Great Britain for multiple cancer types.We had multiple,positive phase 3 data readouts,suppor

3、ting regulatory submissions for approval of the ENHANZE subcutaneous(SC)formulations for argenxs VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy(CIDP),Roches ocrelizumab SC for multiple sclerosis and Bristol Myers Squibbs nivolumab SC for cancer.We added a new ENHANZE partner,A

4、cumen Pharmaceuticals,for the potential use of ENHANZE for ACU193,Acumens clinical stage monoclonal antibody candidate to target Amyloid-Oligomers for the treatment of early Alzheimers disease.We achieved an important milestone for our new high-volume auto-injector,successfully demonstrating the fea

5、sibility of administering a subcutaneous injection of 10 mLs of a representative biologic,immunoglobulin 10%with ENHANZE,in approximately 30 seconds using our high volume auto-injector.As I reflect on the achievements of the past year,I am proud of the growth and progress accomplished during 2023.It

6、 has been a year of many successes and significant impact as we made progress with our commitment to advance new solutions for patients.At the heart of our vision is an unyielding dedication to the patients we serve.Today,many breakthrough therapies require the patients life to fit the treatment.Our